Pyrrole substituted 2-indolinone protein kinase inhibitors

1. A compound of Formula (I):

• wherein;
  
  R¹ is selected from the group consisting of hydrogen, halo, alkyl, cyclkoalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, —
  
  (CO)R¹⁵, —
  
  NR¹³R¹⁴, —
  
  (CH₂)_rR¹⁶ and —
  
  C(O)NR⁸R⁹;
  
  R² is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, —
  
  NR¹³R¹⁴, —
  
  NR¹³C(O)R¹⁴, —
  
  C(O)R¹⁵, aryl, heteroaryl, and —
  
  S(O)₂NR¹³R¹⁴;
  
  R³ is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, —
  
  (CO)R¹⁵, —
  
  NR¹³R¹⁴, aryl, heteroaryl, —
  
  NR¹³S(O)₂R¹⁴, —
  
  S(O)₂NR¹³R¹⁴, —
  
  NR¹³C(O)R¹⁴, —
  
  NR¹³C(O)OR¹⁴ and —
  
  SO₂R²⁰(wherein R²⁰ is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);
  
  R⁴ is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and —
  
  NR¹³R¹⁴ R⁵ is selected from the group consisting of hydrogen and alkyl;
  
  R⁶ is —
  
  C(O)R¹⁰ wherein R¹⁰ is —
  
  NR¹¹(CH₂)_nR¹² wherein;
  
  R¹¹ is hydrogen or lower unsubstituted alkyl;
  
  n is 2 or 3; and
  
  R¹² is —
  
  NR¹³R¹⁴ or —
  
  N⁺(O)R¹³R¹⁴;
  
  R⁷ is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl;
  
  R⁸ and R⁹ are independently selected from the group consisting of hydrogen, alkyl and aryl;
  
  R¹³ and R¹⁴ are independently selected from the group consisting of hydrogen, alkyl, lower alkyl substituted with hydroxy, alkylamino, cyanoalkyl, cycloalkyl, aryl and heteroaryl;
  
  or R¹³ and R¹⁴ may combine to form a heterocyclo group;
  
  R¹⁵ is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;
  
  R¹⁶ is selected from the group consisting of hydroxy, —
  
  C(O)R¹⁵, —
  
  NR¹³R¹⁴ and —
  
  C(O)NR¹³R¹⁴; and
  
  r is 1, 2, 3, or 4;
  
  or a pharmaceutically acceptable salt thereof.